Legal & General Group
PHAT icon

Legal & General Group’s Phathom Pharmaceuticals PHAT Stock Holding History

Legal & General Group’s Portfolio PHAT Stock Details PHAT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$355K Buy
32,738
+701
+2% +$8K ﹤0.01% 2469
2026
Q1 		$356K Sell
32,037
-2,212
-6% -$27.9K ﹤0.01% 2445
2025
Q4 		$568K Buy
34,249
+30,162
+738% +$431K ﹤0.01% 2388
2025
Q3 		$48.1K Hold
4,087
– – ﹤0.01% 2741
2025
Q2 		$39.2K Sell
4,087
-32,351
-89% -$179K ﹤0.01% 2759
2025
Q1 		$229K Hold
36,438
– – ﹤0.01% 2591
2024
Q4 		$296K Buy
36,438
+2,060
+6% +$25.5K ﹤0.01% 2607
2024
Q3 		$622K Buy
34,378
+53
+0.2% +$741 ﹤0.01% 2387
2024
Q2 		$354K Buy
34,325
+223
+0.7% +$2.3K ﹤0.01% 2543
2024
Q1 		$362K Sell
34,102
-151
-0.4% -$1.28K ﹤0.01% 2550
2023
Q4 		$313K Buy
34,253
+251
+0.7% +$2.16K ﹤0.01% 2614
2023
Q3 		$353K Buy
34,002
+1,726
+5% +$23.7K ﹤0.01% 2565
2023
Q2 		$462K Buy
32,276
+28,358
+724% +$327K ﹤0.01% 2488
2023
Q1 		$28K Sell
3,918
-3,503
-47% -$30.8K ﹤0.01% 2978
2022
Q4 		$83.3K Hold
7,421
– – ﹤0.01% 2857
2022
Q3 		$82K Buy
7,421
+1,093
+17% +$10.4K ﹤0.01% 2870
2022
Q2 		$54K Buy
6,328
+1,061
+20% +$10.9K ﹤0.01% 2993
2022
Q1 		$72K Buy
5,267
+89
+2% +$1.44K ﹤0.01% 2935
2021
Q4 		$102K Hold
5,178
– – ﹤0.01% 2904
2021
Q3 		$167K Buy
5,178
+2,739
+112% +$91K ﹤0.01% 2737
2021
Q2 		$82K Buy
2,439
+888
+57% +$31.8K ﹤0.01% 2797
2021
Q1 		$58K Sell
1,551
-72
-4% -$3.01K ﹤0.01% 2775
2020
Q4 		$54K Buy
1,623
+300
+23% +$12.2K ﹤0.01% 2777
2020
Q3 		$49K Sell
1,323
-489
-27% -$16.9K ﹤0.01% 2702
2020
Q2 		$60K Buy
1,812
+196
+12% +$7.53K ﹤0.01% 2681
2020
Q1 		$42K Sell
1,616
-501
-24% -$16.7K ﹤0.01% 2657
2019
Q4 		$66K Buy
+2,117
New +$53.2K ﹤0.01% 2717

Other funds holding PHAT

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
MVM
Medicxi Ventures Management St. Helier, Jersey $177M AUM 212.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10B AUM 10.61% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
GKIM
GW&K Investment Management Boston, Massachusetts $12.8B AUM 48.82% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Legal & General Group's PHAT Position: Q2 2026 in Review

Legal & General Group increased its Phathom Pharmaceuticals (PHAT) stake by 2.2% in Q2 2026, buying an estimated $8K and bringing the position to 32,738 shares worth $355K. The position accounts for ﹤0.01% of the portfolio, ranked #2469.

Legal & General Group first reported a position in PHAT in Q4 2019 and has held it in 27 quarters since. The position peaked at $622K in Q3 2024. 161 funds tracked by Wall St. Rank hold PHAT as of Q2 2026.

  • Legal & General Group held 32,738 shares of Phathom Pharmaceuticals worth $355K as of Q2 2026.
  • Legal & General Group bought 701 Phathom Pharmaceuticals shares in Q2 2026, an estimated $8K.
  • Phathom Pharmaceuticals made up ﹤0.01% of Legal & General Group's portfolio in Q2 2026, its #2469 holding.
  • Legal & General Group first reported a position in Phathom Pharmaceuticals in Q4 2019 and has held it in 27 quarters since.
  • Legal & General Group's Phathom Pharmaceuticals position peaked at $622K in Q3 2024.
  • 161 funds tracked by Wall St. Rank held Phathom Pharmaceuticals as of Q2 2026.

Based on Legal & General Group's 13F filing for Q2 2026, filed 14 Aug 2026.